三苯甲基肼 | 104933-75-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 中文名称: 三苯甲基肼
• 中文别名: N-三苯代甲基酰肼
• 英文名称: triphenylmethylhydrazine
• 英文别名: trityl-hydrazine；Trityl-hydrazin；Triphenylmethyl-hydrazin；α-Hydrazino-triphenylmethan；(Triphenylcarbin)-hydrazin；Tritylhydrazine
• CAS: 104933-75-7
• 化学式: C₁₉H₁₈N₂
• 分子量: 274.365
• InChiKey: XUECSRVFRKTFKJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2928000090

反应信息

• 作为反应物：
  描述：

  三苯甲基肼 在 盐酸 、 乙醇 、 sodium nitrite 作用下， 生成 叠氮化三苯基甲烷
  参考文献：
  名称：

  Wieland, Chemische Berichte, 1909, vol. 42, p. 3021

  摘要：

  DOI：
• 作为产物：
  描述：

  triphenylmethyl 4-cyanophenyl ether 在 sodium sulfate 、 肼 作用下， 以 水 为溶剂， 生成 三苯甲基肼
  参考文献：
  名称：

  三苯甲基碳正离子在水溶液中的亲电反应性

  摘要：

  形成du cation tricyclium etude de sa reactive vis-a-vis de nucleophiles neutres et ioniques

  DOI：

  10.1021/ja00282a029

文献信息

• Synthesis of N-(protected)aminophthalimides: application to the synthesis of singly labelled isoniazid
  作者：Nicolas Brosse、Maria-Fatima Pinto、Brigitte Jamart-Grégoire

  DOI：10.1039/a807230b

  日期：——

  The synthesis of a series of N-(protected)aminophthalimides and the removal of their phthaloyl group leading to N-(protected) or N,N-bis(protected)hydrazines is described. As illustrated by the synthesis of monolabelled isoniazid 3b*, this strategy can be utilized for the preparation of monolabelled substituted hydrazines.

  本文描述了一系列N-（保护）氨基邻苯二甲酰亚胺的合成及其邻苯二甲酰基团的去除，从而得到N-（保护）或N,N-双（保护）联氨。合成单标记的异烟肼3b*的过程表明，这一策略可用于制备单标记的取代联氨。
• CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE
  申请人：ZECRI Frederic

  公开号：US20150031604A1

  公开（公告）日：2015-01-29

  The invention provides a cyclic polypeptide of Formula I (SEQ ID NO: 1): X1-R-X3-X4-L-S-X7-X8-X9-X10-X11-X12-X13  I or an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein X1, X3, X4, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention or bioconjugates thereof, and their therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  该发明提供了Formula I（序列ID号：1）的循环多肽：X1-R-X3-X4-L-S-X7-X8-X9-X10-X11-X12-X13，或者其酰胺、酯或盐，或其生物结合物，其中X1、X3、X4、X7、X8、X9、X10、X11、X12和X13在此有定义。这些多肽是APJ受体的激动剂。该发明还涉及一种制造该发明的多肽或其生物结合物的方法，以及它们的治疗用途，如治疗或预防急性失代偿性心力衰竭（ADHF）、慢性心力衰竭、肺动脉高压、心房颤动、布加达综合征、室性心动过速、动脉粥样硬化、高血压、再狭窄、缺血性心血管疾病、心肌病、心肌纤维化、心律失常、水潴留、糖尿病（包括妊娠糖尿病）、肥胖、周围动脉疾病、脑血管意外、短暂性脑缺血发作、创伤性脑损伤、肌萎缩侧索硬化、烧伤（包括晒伤）和子痫的组合。本发明还提供了药理活性剂的组合和制药组合。
• CYCLIC APELIN DERIVATIVES FOR THE TREATMENT OF HEART FAILURE
  申请人：ZECRI Frédéric

  公开号：US20160159871A1

  公开（公告）日：2016-06-09

  The invention provides a synthetic polypeptide of Formula I′: X1-R-X3-R-L-X6-X7-K-X9-P-X11-X12-X13 or an amide, an ester, a salt thereof, or a bioconjugate thereof, wherein X1, X3, X6, X7, X9, X11, X12 and X13 are defined herein. The polypeptides and bioconjugates are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides and bioconjugates of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  该发明提供了式I′的合成多肽：X1-R-X3-R-L-X6-X7-K-X9-P-X11-X12-X13或其酰胺、酯、盐或生物结合物，其中X1、X3、X6、X7、X9、X11、X12和X13在此处定义。这些多肽和生物结合物是APJ受体的激动剂。该发明还涉及一种制造该发明的多肽和生物结合物的方法，以及其治疗用途，如治疗或预防急性失代偿性心力衰竭（ADHF）、慢性心力衰竭、肺动脉高压、心房颤动、布加达综合征、室性心动过速、动脉粥样硬化、高血压、再狭窄、缺血性心血管疾病、心肌病、心脏纤维化、心律失常、水潴留、糖尿病（包括妊娠期糖尿病）、肥胖、周围动脉疾病、脑血管意外、短暂性缺血性发作、创伤性脑损伤、肌萎缩侧索硬化、烧伤（包括晒伤）和子痫的组合。本发明还提供了药理活性剂的组合和制药组合物。
• Antibody-mediated disruption of quorum sensing in bacteria
  申请人：Janda Kim D.

  公开号：US09394371B2

  公开（公告）日：2016-07-19

  The invention provides an immunogenic molecular entity, a supramolecular assembly, and an antibody that can be used to inhibit Gram-positive bacterial quorum sensing, prevent infection or development of a disease condition associated with a Gram-positive bacterial infection. The invention also provides methods of inhibiting Gram-positive bacterial quorum sensing, and methods of preventing infection or development of a disease condition associated with a Gram-positive bacterial infection.

  该发明提供了一种免疫原子实体、一个超分子组装体和一种抗体，可用于抑制革兰氏阳性细菌的群体感应、预防与革兰氏阳性细菌感染相关的疾病或病情的发展。该发明还提供了抑制革兰氏阳性细菌群体感应的方法，以及预防与革兰氏阳性细菌感染相关的疾病或病情发展的方法。
• DISULFIDE CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE
  申请人：ZECRI Frédéric

  公开号：US20160145309A1

  公开（公告）日：2016-05-26

  The invention provides a synthetic polypeptide of Formula I′: X1-R-P-R-X5-X6-X7-K-X9-P-X11-X12-X13 or an amide, an ester, a salt or a bioconjugate thereof, wherein X1, X5, X6, X7, X9 and X11 to X13 are defined herein. The polypeptides and bioconjugates are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides or bioconjugates of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  该发明提供了公式I′的合成多肽：X1-R-P-R-X5-X6-X7-K-X9-P-X11-X12-X13或其酰胺、酯、盐或生物结合物，其中X1、X5、X6、X7、X9和X11至X13在此处定义。这些多肽和生物结合物是APJ受体的激动剂。该发明还涉及一种制造该发明的多肽或生物结合物的方法，以及其治疗用途，如治疗或预防急性失代偿性心力衰竭（ADHF）、慢性心力衰竭、肺动脉高压、心房颤动、布氏综合征、室性心动过速、动脉粥样硬化、高血压、再狭窄、缺血性心血管疾病、心肌病、心脏纤维化、心律失常、水潴留、糖尿病（包括妊娠期糖尿病）、肥胖、外周动脉疾病、脑血管意外、短暂性脑缺血发作、创伤性脑损伤、肌萎缩侧索硬化、烧伤（包括晒伤）和子痫前症。本发明进一步提供了药理活性剂的组合和制药组合物。